Freeline_Logo_Red_RGB.jpg
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
January 06, 2022 07:00 ET | Freeline Therapeutics
FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 ...
Freeline_Logo_Red_RGB.jpg
Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results
November 09, 2021 16:01 ET | Freeline Therapeutics
Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease
September 09, 2021 07:00 ET | Freeline Therapeutics
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline_Logo_Red_RGB.jpg
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™
February 08, 2021 16:01 ET | Freeline Therapeutics
Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease ...
CENTOGENElogo.jpg
CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease
August 20, 2020 01:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...